BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

296 related articles for article (PubMed ID: 33277241)

  • 1. Monocyte and bone marrow macrophage transcriptional phenotypes in systemic juvenile idiopathic arthritis reveal TRIM8 as a mediator of IFN-γ hyper-responsiveness and risk for macrophage activation syndrome.
    Schulert GS; Pickering AV; Do T; Dhakal S; Fall N; Schnell D; Medvedovic M; Salomonis N; Thornton S; Grom AA
    Ann Rheum Dis; 2021 May; 80(5):617-625. PubMed ID: 33277241
    [TBL] [Abstract][Full Text] [Related]  

  • 2. IFN-γ is essential for alveolar macrophage-driven pulmonary inflammation in macrophage activation syndrome.
    Gao DK; Salomonis N; Henderlight M; Woods C; Thakkar K; Grom AA; Thornton S; Jordan MB; Wikenheiser-Brokamp KA; Schulert GS
    JCI Insight; 2021 Sep; 6(17):. PubMed ID: 34314387
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cytokines in systemic juvenile idiopathic arthritis and haemophagocytic lymphohistiocytosis: tipping the balance between interleukin-18 and interferon-γ.
    Put K; Avau A; Brisse E; Mitera T; Put S; Proost P; Bader-Meunier B; Westhovens R; Van den Eynde BJ; Orabona C; Fallarino F; De Somer L; Tousseyn T; Quartier P; Wouters C; Matthys P
    Rheumatology (Oxford); 2015 Aug; 54(8):1507-17. PubMed ID: 25767156
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adenosine deaminase 2 as a biomarker of macrophage activation syndrome in systemic juvenile idiopathic arthritis.
    Lee PY; Schulert GS; Canna SW; Huang Y; Sundel J; Li Y; Hoyt KJ; Blaustein RB; Wactor A; Do T; Halyabar O; Chang MH; Dedeoglu F; Case SM; Meidan E; Lo MS; Sundel RP; Richardson ET; Newburger JW; Hershfield MS; Son MB; Henderson LA; Nigrovic PA
    Ann Rheum Dis; 2020 Feb; 79(2):225-231. PubMed ID: 31707357
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Follistatin-like protein 1 and the ferritin/erythrocyte sedimentation rate ratio are potential biomarkers for dysregulated gene expression and macrophage activation syndrome in systemic juvenile idiopathic arthritis.
    Gorelik M; Fall N; Altaye M; Barnes MG; Thompson SD; Grom AA; Hirsch R
    J Rheumatol; 2013 Jul; 40(7):1191-9. PubMed ID: 23678162
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Elevated circulating levels of interferon-γ and interferon-γ-induced chemokines characterise patients with macrophage activation syndrome complicating systemic juvenile idiopathic arthritis.
    Bracaglia C; de Graaf K; Pires Marafon D; Guilhot F; Ferlin W; Prencipe G; Caiello I; Davì S; Schulert G; Ravelli A; Grom AA; de Min C; De Benedetti F
    Ann Rheum Dis; 2017 Jan; 76(1):166-172. PubMed ID: 27296321
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sudden Hypotension and Increased Serum Interferon-γ and Interleukin-10 Predict Early Macrophage Activation Syndrome in Patients with Systemic Juvenile Idiopathic Arthritis.
    Guo L; Xu Y; Qian X; Zou L; Zheng R; Teng L; Zheng Q; Leung Jung LK; Lu M
    J Pediatr; 2021 Aug; 235():203-211.e3. PubMed ID: 33581106
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MicroRNA networks associated with active systemic juvenile idiopathic arthritis regulate CD163 expression and anti-inflammatory functions in macrophages through two distinct mechanisms.
    Do T; Tan R; Bennett M; Medvedovic M; Grom AA; Shen N; Thornton S; Schulert GS
    J Leukoc Biol; 2018 Jan; 103(1):71-85. PubMed ID: 29345059
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Systemic juvenile idiopathic arthritis and recurrent macrophage activation syndrome due to a CASP1 variant causing inflammasome hyperactivation.
    Jørgensen SE; Christiansen M; Høst C; Glerup M; Mahler B; Lausten MM; Gad HH; Hartmann R; Herlin T; Mogensen TH
    Rheumatology (Oxford); 2020 Oct; 59(10):3099-3105. PubMed ID: 32556329
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The frequency of macrophage activation syndrome and disease course in systemic juvenile idiopathic arthritis.
    Çakan M; Karadağ ŞG; Tanatar A; Ayaz NA
    Mod Rheumatol; 2020 Sep; 30(5):900-904. PubMed ID: 31462146
    [No Abstract]   [Full Text] [Related]  

  • 11. IDO1 Deficiency Does Not Affect Disease in Mouse Models of Systemic Juvenile Idiopathic Arthritis and Secondary Hemophagocytic Lymphohistiocytosis.
    Put K; Brisse E; Avau A; Imbrechts M; Mitera T; Janssens R; Proost P; Fallarino F; Wouters CH; Matthys P
    PLoS One; 2016; 11(2):e0150075. PubMed ID: 26914138
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neutrophils From Children With Systemic Juvenile Idiopathic Arthritis Exhibit Persistent Proinflammatory Activation Despite Long-Standing Clinically Inactive Disease.
    Brown RA; Henderlight M; Do T; Yasin S; Grom AA; DeLay M; Thornton S; Schulert GS
    Front Immunol; 2018; 9():2995. PubMed ID: 30619348
    [No Abstract]   [Full Text] [Related]  

  • 13. Systemic Juvenile Idiopathic Arthritis-Associated Lung Disease: Characterization and Risk Factors.
    Schulert GS; Yasin S; Carey B; Chalk C; Do T; Schapiro AH; Husami A; Watts A; Brunner HI; Huggins J; Mellins ED; Morgan EM; Ting T; Trapnell BC; Wikenheiser-Brokamp KA; Towe C; Grom AA
    Arthritis Rheumatol; 2019 Nov; 71(11):1943-1954. PubMed ID: 31379071
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Performance of interferon-gamma levels may lead to earlier diagnosing macrophage activation syndrome complicating systemic juvenile idiopathic arthritis.
    Lu M; Teng L; Xu Y; Xu X
    Pediatr Rheumatol Online J; 2023 Oct; 21(1):115. PubMed ID: 37828529
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development and initial validation of the MS score for diagnosis of macrophage activation syndrome in systemic juvenile idiopathic arthritis.
    Minoia F; Bovis F; Davì S; Horne A; Fischbach M; Frosch M; Huber A; Jelusic M; Sawhney S; McCurdy DK; Silva CA; Rigante D; Unsal E; Ruperto N; Martini A; Cron RQ; Ravelli A;
    Ann Rheum Dis; 2019 Oct; 78(10):1357-1362. PubMed ID: 31296501
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Altered signaling in systemic juvenile idiopathic arthritis monocytes.
    Macaubas C; Wong E; Zhang Y; Nguyen KD; Lee J; Milojevic D; Shenoi S; Stevens AM; Ilowite N; Saper V; Lee T; Mellins ED
    Clin Immunol; 2016 Feb; 163():66-74. PubMed ID: 26747737
    [TBL] [Abstract][Full Text] [Related]  

  • 17. IL-18 as a biomarker linking systemic juvenile idiopathic arthritis and macrophage activation syndrome.
    Yasin S; Fall N; Brown RA; Henderlight M; Canna SW; Girard-Guyonvarc'h C; Gabay C; Grom AA; Schulert GS
    Rheumatology (Oxford); 2020 Feb; 59(2):361-366. PubMed ID: 31326996
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Monocytes From Patients With Macrophage Activation Syndrome and Secondary Hemophagocytic Lymphohistiocytosis Are Hyperresponsive to Interferon Gamma.
    Pascarella A; Bracaglia C; Caiello I; Arduini A; Moneta GM; Rossi MN; Matteo V; Pardeo M; De Benedetti F; Prencipe G
    Front Immunol; 2021; 12():663329. PubMed ID: 33815425
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Systemic juvenile idiopathic arthritis and macrophage activation syndrome: update on pathogenesis and treatment.
    Yasin S; Schulert GS
    Curr Opin Rheumatol; 2018 Sep; 30(5):514-520. PubMed ID: 29870499
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Single center clinical analysis of macrophage activation syndrome complicating juvenile rheumatic diseases.
    Huang S; Liu Y; Yan W; Zhang T; Wang P; Zhu M; Zhang X; Zhou P; Fan Z; Yu H
    Pediatr Rheumatol Online J; 2024 May; 22(1):58. PubMed ID: 38783316
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.